Clinical Trials Arena is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Tretten for the Treatment of Congenital Factor XIII Deficiency

Drug Name (Brand / Generic)

Tretten / coagulation Factor XIII ASubunit (Recombinant)

Developed by

Novo Nordisk

Therapy Class

Recombinant DNA

Current Indication

Congenital Factor XIII Deficiency

Market Sector

Haematology

Development Status

Approved in the US, Canada, Europe, Switzerland and Australia
Expand
Close
Close
Close

Go Top